--- title: "Dynavax Tech (DVAX.US)" type: "Symbol" locale: "en" url: "https://longbridge.com/en/quote/DVAX.US.md" symbol: "DVAX.US" name: "Dynavax Tech" industry: "Biotechnology" datetime: "2026-03-12T18:47:41.995Z" locales: - [en](https://longbridge.com/en/quote/DVAX.US.md) - [zh-CN](https://longbridge.com/zh-CN/quote/DVAX.US.md) - [zh-HK](https://longbridge.com/zh-HK/quote/DVAX.US.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/DVAX.US.md) | [繁體中文](https://longbridge.com/zh-HK/quote/DVAX.US.md) # Dynavax Tech (DVAX.US) ## Company Overview Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vaccine candidate in Phase 1/2 clinical trial for the prevention of shingles in adults aged 50 years and older, as well as HEPLISAV-B for adults on hemodialysis. The company sells its products to hospitals and clinics, integrated delivery networks, public health clinics and prisons, the Department of Defense, the Department of Veterans Affairs, and retail pharmacies through wholesalers and specialty distributors. | Item | Detail | |------|--------| | Industry | Biotechnology | | Exchange | US Market | ## Key Drivers > *AI-analyzed key factors driving this stock's performance* ## Longbridge Financial Score™: C > *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge* > Updated: 2026-03-12T04:30:15.000Z **Overall: C (0.53)** **Industry**: Biotechnology | Metric | Value | |--------|-------| | Industry Ranking | 0 / 406 | | Industry Median | D | | Industry Average | C | - **Style**: Blend - Stocks in which the company has both growth and mature businesses. - **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns. **Multi Score**: C #### Style Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | 26.73% | | | Net Profit YoY | -311.94% | | | P/B Ratio | 0.00 | | | Dividend Ratio | 0.00% | | #### Size Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Market Cap | 0.00 | | | Revenue | 330514000.00 | | #### Multi Score Score: C | Indicator | Value | Rating | |-----------|-------|--------| | ROE | -7.14% | D | | Profit Margin | -13.13% | D | | Gross Margin | 65.35% | A | | Revenue YoY | 26.73% | A | | Net Profit YoY | -311.94% | E | | Total Assets YoY | -10.87% | E | | Net Assets YoY | -21.61% | E | | Cash Flow Margin | -761.54% | E | | OCF YoY | 26.73% | A | | Turnover | 0.33 | D | | Gearing Ratio | 43.57% | C | ```chart-data:radar { "title": "Longbridge Financial Score - Dynavax Tech", "chart_type": "radar", "dimensions": [ { "name": "Style Score", "grade": "", "indicators": [ { "name": "Revenue YoY", "value": "26.73%", "rating": "" }, { "name": "Net Profit YoY", "value": "-311.94%", "rating": "" }, { "name": "P/B Ratio", "value": "0.00", "rating": "" }, { "name": "Dividend Ratio", "value": "0.00%", "rating": "" } ] }, { "name": "Size Score", "grade": "", "indicators": [ { "name": "Market Cap", "value": "0.00", "rating": "" }, { "name": "Revenue", "value": "330514000.00", "rating": "" } ] }, { "name": "Multi Score", "grade": "C", "indicators": [ { "name": "ROE", "value": "-7.14%", "rating": "D" }, { "name": "Profit Margin", "value": "-13.13%", "rating": "D" }, { "name": "Gross Margin", "value": "65.35%", "rating": "A" }, { "name": "Revenue YoY", "value": "26.73%", "rating": "A" }, { "name": "Net Profit YoY", "value": "-311.94%", "rating": "E" }, { "name": "Total Assets YoY", "value": "-10.87%", "rating": "E" }, { "name": "Net Assets YoY", "value": "-21.61%", "rating": "E" }, { "name": "Cash Flow Margin", "value": "-761.54%", "rating": "E" }, { "name": "OCF YoY", "value": "26.73%", "rating": "A" }, { "name": "Turnover", "value": "0.33", "rating": "D" }, { "name": "Gearing Ratio", "value": "43.57%", "rating": "C" } ] } ] } ``` ## Valuation Analysis | Metric | Current | Industry Ranking | High | Median | Low | |--------|---------|-----------------|------|--------|-----| | PE (TTM) | -40.60 | 544/406 | 62.15 | 54.65 | 49.84 | | PB | 3.30 | 247/406 | 3.29 | 2.43 | 2.31 | | PS (TTM) | 5.33 | 100/406 | 5.33 | 4.15 | 3.84 | | Dividend Yield | 0.00% | - | - | - | - | ## Peer Comparison | Rank | Name | Profit | Growth | Operation | Security | Cash | Rating | | --- | --- | --- | --- | --- | --- | --- | --- | | 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A | | 02 | Stoke Therapeutics (STOK.US) | A | A | B | A | B | A | | 03 | MiMedx (MDXG.US) | A | B | A | B | B | A | | 04 | Rigel Pharma (RIGL.US) | A | A | B | B | B | A | | 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A | ## Institutional View ### Analyst Rating Distribution > As of 2025-12-24T05:00:00.000Z Total Analysts: **3** | Rating | Count | Percentage | |--------|-------|-----------| | Buy | 1 | 33% | | Hold | 1 | 33% | | Sell | 1 | 33% | ### Target Price Forecast | Metric | Price | |--------|-------| | Current Price | 15.50 | | Highest Target | 25.00 | | Lowest Target | 16.00 | ## References - [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/DVAX.US/overview.md) - [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/DVAX.US/norm.md) - [Related News](https://longbridge.com/en/quote/DVAX.US/news.md) - [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/DVAX.US/filings.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**